Table V.

Univariate and multivariate analysis of overall survival and progression-free survival of patients treated with combination Len + TACE and TACE monotherapy.

	Overall survival				Progression-free survival
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
Patient characteristic	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
Age, years	0.998 (0.970–1.027)	0.892	N/A	N/A	1.020 (0.996–1.044)	0.107	N/A	N/A
Sex
Male vs. female	0.643 (0.220–1.879)	0.419	N/A	N/A	0.774 (0.303–1.977)	0.592	N/A	N/A
HBV
Positive vs. negative	0.756 (0.259–2.203)	0.608	N/A	N/A	0.726 (0.304–1.731)	0.470	N/A	N/A
AFP, ng/l
>400 vs. ≤400	1.192 (0.544–2.613)	0.661	N/A	N/A	1.123 (0.604–2.091)	0.714	N/A	N/A
Child-Pugh score
6 vs. 5	0.697 (0.265–1.833)	0.465	N/A	N/A	0.672 (0.326–1.385)	0.282	N/A	N/A
7 vs. 5	1.620 (0.638–4.111)	0.310	N/A	N/A	0.982 (0.449–2.150)	0.964	N/A	N/A
Liver cirrhosis
Yes vs. no	1.201 (0.502–2.876)	0.681	N/A	N/A	0.816 (0.420–1.585)	0.548	N/A	N/A
Tumor number
>3 vs. ≤3	1.437 (0.430–4.801)	0.556	N/A	N/A	1.664 (0.651–4.252)	0.287	N/A	N/A
Largest tumor size, cm
>4 vs. ≤4	4.297 (1.709–10.806)	0.002	4.086 (1.623–10.289)	0.003 (1.334–4.870)	2.548	0.005 (1.334–4.870)	2.548	0.005
Tumor distribution
Bilobar vs. Unilobar	1.394 (0.478–4.066)	0.543	N/A	N/A	1.099 (0.506–2.387)	0.811	N/A	N/A
Treatment
Len + TACE vs. TACE	0.394 (0.170–0.914)	0.030	0.426 (0.184–0.990)	0.047 (0.438–1.515)	0.815	0.517	N/A	N/A

Only variables with P<0.05 at univariate analysis were analyzed by multivariate analysis. Len, lenvatinib; TACE, transarterial chemoembolization; HBV, hepatitis B virus; AFP, α-fetoprotein; HR, hazard ratio; CI, confidence interval; N.A, not applicable.